

Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells

Ulrike Olszewski
Robert Zeillinger
Klaus Geissler
Gerhard Hamilton

Ludwig Boltzmann Cluster of
Translational Oncology, Ludwig
Boltzmann Society, Vienna, Austria

Purpose: Carcinoids are highly chemoresistant tumors associated with a dismal prognosis. This study involved a comparison of the genome-wide gene expression pattern of a chemoresistant and a chemosensitive pulmonary carcinoid cell line to reveal factors that contribute to the resistant phenotype.

Materials and methods: Gene expression of UMC-11 chemoresistant carcinoid cells as assessed by 32 K microarray was compared with H835 chemosensitive carcinoid cells, and the genes that were differentially expressed and expected to be related to chemoresistance were selected.

Results: Drug-resistant UMC-11 cells exhibited increased expression of transcripts known to confer resistance to different cytostatics such as P-glycoprotein, multidrug resistance-associated proteins 2 and 3, effectors of the glutathione detoxification and xenobiotics degradation pathways, and ion transporters including Na⁺/K⁺-adenosine triphosphatase. In addition, enhanced transcription of several S100 proteins, capable of suppressing apoptosis, regulation of topoisomerase I (topo I) expression by antisense transcripts from *TOPO1* pseudogenes, and alterations of the cytoskeleton seem to contribute to the multidrug-resistant phenotype. A multitude of epidermal growth factor (EGF)-related and neuropeptide growth factors, overexpression of proteases, and appearance of aerobic glycolytic metabolism complement the malignant phenotype of the UMC-11 cells.

Conclusion: The multidrug-resistant phenotype of the UMC-11 pulmonary carcinoid cell line seems to be mediated by classical efflux pumps, drug metabolism or conjugation systems, and, possibly, modulation of apoptotic cell death by S100 proteins and topo I expression by pseudogene transcripts. Autocrine or paracrine stimulation by a host of EGF-related and neuropeptide growth factors, as well as high metastatic potency indicated by increased expression of components of aerobic glycolysis and proteolytic enzymes, may furthermore account for the failure of therapeutic interventions.

Keywords: neuroendocrine tumor, drug resistance, microarray, drug transporter, apoptosis

Introduction

Pulmonary carcinoid tumors are considered low-grade malignant neoplasms of the neuroendocrine cells, originating from the Kulchitsky cells of the bronchial mucosa layer, and represent about 1%–5% of all lung tumors.^{1–3} Ninety percent of these tumors termed *typical carcinoids* are well differentiated and characterized by a small degree of mitosis, pleomorphism, and necrosis.^{4,5} The remaining 10% of the tumors with increased mitotic activity, nuclear pleomorphism, and cellular irregularity are classified as aggressive *atypical carcinoids*.^{6,7} The patients with lung carcinoids can be cured by surgical resection, but a fraction of tumors gives rise to widespread metastasis within

Correspondence: Gerhard Hamilton
Ludwig Boltzmann Cluster of Translational
Oncology, c/o Balderichgasse 26/13,
A-1170 Vienna, Austria
Tel +43 | 40400 6627
Fax +43 | 40400 6627
Email gerhard.hamilton@toc.lbg.ac.at

several years after primary treatment.^{8,9} In contrast to the more indolent, well-differentiated neuroendocrine tumors exhibiting metastases in less than 15% of cases and revealing a 5-year survival rate of more than 90%, well-differentiated neuroendocrine carcinomas are more aggressive, develop metastases in 30%–50% of cases, and yield a 5-year survival rate between 40% and 60%.^{1,2,10} Almost all recurrences of either typical or atypical carcinoids involve distant sites. Finally, patients with malignant carcinoids show a 5-year survival rate of about 20% and a median survival of 2 years in the presence of liver metastases.¹¹ Medical treatment of metastatic disease includes somatostatin (SST) analogs, α -interferons, and chemotherapy.^{1,12}

Basically, chemotherapy can be considered for patients with carcinoids progredient under noncytotoxic therapy, provided that they have significant symptoms and poor prognosis.^{13,14} Clinical trials demonstrated that the response rates to single-agent chemotherapy limited to approximately 20%, and for multiagent chemotherapy, the response rates are invariably less than 40%. Moreover, these responses are frequently short-lived and rarely translate to prolonged survival. In contrast, responses of rapidly proliferating, poorly differentiated (atypical or small cell-like) carcinoid tumors to chemotherapy are high but the duration of response is extremely short. In these studies, doxorubicin, 5-fluorouracil (5-FU), dacarbazine, streptozotocin, cyclophosphamide, cisplatin, and etoposide were used either as single agents or in combinations, but eventually were not recommended for clinical routine practice due to low response rates.^{1,3,11,15} The situation is complicated by the fact that these clinical trials are usually small studies with variable criteria for inclusion and study design due to the rarity of these tumors. Little is known about the mechanisms contributing to chemoresistance of carcinoids or other well-differentiated neuroendocrine tumors. Screening of chemosensitivities of UMC-11, H727, and H835 pulmonary carcinoid cell lines in the laboratory revealed the resistance of UMC-11 to 9 of 14 chemotherapeutics, whereas H727 and H835 were resistant to 4 of 14 and 5 of 14 of the drugs, respectively.¹⁶ Because doubling times were 20.8 hours for H727, 27.0 hours for UMC-11, and 35.7 hours for H835 cells, the more rapidly proliferating and, therefore, probably more chemosensitive H727 cell line was not used in the following gene expression analysis.¹⁶ The aim of this study was to compare the transcriptome of the highly chemoresistant UMC-11 with the sensitive H835 cell line to delineate candidate genes possibly conferring multidrug resistance to pulmonary carcinoids.

Materials and methods

Chemicals and cell lines

Unless otherwise noted, all chemicals and solutions were obtained from Sigma-Aldrich (St. Louis, MO). UMC-11 and H835 pulmonary carcinoid cell lines were purchased from the American Tissue Culture Collection (Manassas, VA). Cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Seromed, Berlin, Germany), 4 mM glutamine, and antibiotics. UMC-11 was subcultured by trypsinization (2.5% trypsin in EDTA solution; Boehringer Mannheim, Germany), and H835 cells growing in suspension were maintained by replacement of the medium and dispersed by trypsin treatment.

Cell proliferation assay

Cells were harvested, counted, and distributed into the wells of flat-bottomed 96-well microtiter plates at a density of 1×10^4 cells/well in 100 μ L medium. 100 μ L of appropriate dilutions of test compounds was added to each well, and the plates were incubated under tissue culture conditions for 4 days. Stock solutions of the compounds were prepared in either 70% ethanol or dimethyl sulfoxide and diluted more than 100-fold for use in chemosensitivity assays. Solvent-control wells were included in all tests. Dose–response curves were obtained by the assessment of cell growth at 2-fold drug dilutions in triplicate and used for the calculation of the half maximal inhibitory concentration (IC_{50}) values. Cell proliferation was quantified using a modified tetrazolium dye (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (EZ4U; Biomedica, Vienna, Austria).

Genome-wide gene expression analysis

Lysates of 30×10^6 cells (extraction buffer: 4 M guanidine isothiocyanate, 0.5% sodium *N*-lauroyl sarcosinate, 10 mM EDTA, 5 mM sodium citrate, and 100 μ M β -mercaptoethanol; 30 minutes, 4°C) were added to cesium trifluoroacetate and centrifuged (46,000 rpm, 15°C, 20 h). Supernatant containing DNA was removed and RNA was precipitated with ice-cold 96% ethanol. Pellets were washed and, following removal of ethanol, resuspended in sterile water. RNA content was measured photometrically.

Gene expression analysis was performed using the Applied Biosystems (ABI) Human Genome Survey Microarray V2.0 (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Therefore, 2–5 μ g mRNA (20–50 μ g total RNA) was reversely transcribed (RT) to first-strand cDNA (MyCycler thermocycler; Bio-Rad, Hercules, CA). The RT mixture was labeled on ice and

purified according to the manufacturer's instructions for the Applied Biosystems 1700 RT Labeling Kit v002 (Applied Biosystems). Hybridization of cDNA and microarray analysis (Applied Biosystems 1700) were carried out following the manufacturer's chemiluminescence detection kit protocol. Data for each cell line ($n = 2$) were filtered, normalized, and \log_2 -transformed before further processing was done using Microsoft Excel software (Microsoft, Redmond, WA) or Statistical Analysis of Microarray (false discovery rate of 10%; Stanford University, Stanford, CA). ABI 1700 gene identities can be accessed via the Panther classification system (www.pantherdb.org).

Results

We previously reported the following IC_{50} values (IC_{50} UMC-11/ IC_{50} H835, mean \pm standard deviation) for a range of drugs that were obtained for UMC-11 and H835 cells in chemosensitivity assays: vinblastine (ng/mL), $2 \pm 0.35/2 \pm 0.3$; taxol (ng/mL), $10 \pm 4.4/9 \pm 3.9$; camptothecin (nM), $18 \pm 5.0/6.5 \pm 4.3$; 5-FU (μ M), $30 \pm 4.6/45 \pm 8.7$; doxorubicin (nM), $370 \pm 72/73 \pm 2.4$; gemcitabine (nM), $833 \pm 103/30.0 \pm 20$; tamoxifen (μ M), $9 \pm 3.3/7 \pm 2.4$; cisplatin (μ M), $33 \pm 15/33 \pm 7.0$; oxaliplatin (μ M), $5 \pm 0.25/6 \pm 0.51$; carboplatin (μ M), $36 \pm 7.1/36 \pm 9.9$; mitomycin (ng/mL), $156 \pm 15/35 \pm 9.0$; streptozotocin (μ g/mL), $180 \pm 33/60 \pm 19$; etoposide (μ g/mL), $45 \pm 12.3/0.25 \pm 0.02$; and dacarbazine (μ g/mL), $4 \pm 2.3/16 \pm 3.9$. Thus, UMC-11 cells were resistant to taxol, camptothecin, 5-FU, doxorubicin, gemcitabine, tamoxifen, cisplatin, streptozotocin, and etoposide (IC_{50} exceeding peak plasma concentration).¹⁶

Genome-wide expression analysis was performed for chemoresistant UMC-11 and chemosensitive H835 pulmonary carcinoid cells, and the genes that were significantly overexpressed more than 4-fold in the former cell line compared with the latter were grouped according to their cellular functions and pathways (Table 1). Genes were furthermore selected in regard to their possible relation with the resistant phenotype of the UMC-11 cells. The low number of genes with lower expression in UMC-11 compared with H835 cells was not included in this analysis because of the absence of transcripts with a connection to chemoresistance. After filtering of the 1,520 transcripts that were overexpressed more than 4-fold in UMC-11 compared with H835 carcinoid cells, 386 were annotated to the corresponding genes, and 102 of these are expected to be involved in proliferation, metastasis, and drug resistance of the carcinoid cells, as listed in Table 1.

In UMC-11 cells, enzymes mainly involved in glucose and energy metabolism that were preferentially expressed

included lactate dehydrogenase (*LDH/LDHB*), glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*), hexokinase 1 (*HK1*), citrate synthetase (*CS*), and pyruvate dehydrogenase kinase 4 (*PK4*), indicating differences in glucose uptake and utilization between the 2 cell lines. Increased expression of hypoxia-inducible gene domain family member 1A (*HIG1/HIGD1A*) and aryl hydrocarbon receptor nuclear translocator 2 (*ARNT2*) together with the changes in regard to glucose metabolism pointed to the presence of an increased rate of aerobic glycolysis (Warburg effect) in UMC-11 cells. Furthermore, in these cells, a number of proteases and protease inhibitors were highly expressed, including serine proteases 1–3 (*PRSSI-3*), serine protease inhibitors (*SERPINS A2, E2, B6, and A10*), cathepsin L (*CTSL*), matrix metalloproteinase 13 (*MMP13*, identical to collagenase 3), and the corresponding tissue inhibitors of metalloproteinase 1 and 3 (*TIMPI 1 and 3*). Hypoxia is known to select for an aggressive cancer phenotype characterized by an increased capacity to infiltrate tissues.

In addition, UMC-11 cells showed higher expression of a large number of membrane transporters compared with H835 cells, thus comprising Na^+/K^+ -adenosine triphosphatase ([ATPase], *ATP1B1*), the FXYD regulatory subunit 2 (*FXYD2*), and ion pumps regulating intracellular Ca^{2+} concentration (*ATP2A2, ATP2B1, and ATP2C2*). The subfamily members of ATP-binding cassette (ABC) transporters (*ABCB1, C2, and C3*) resemble the classical resistance proteins P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRPs) 2 and 3. Furthermore, the 2 solute carrier organic anion transporters (*SLCO1A2* and *SLCO2A1*), shuttling bile acids, prostaglandins (PGs), and other anions, and a number of solute carriers transporting aspartate/glutamate (*SLC1A6*), biogenic amines (*SLC18A1*), anions (*SLC4A2*), sodium (*SLC4A11*), potassium chloride (*SLC12A7*), sodium phosphate (*SLC20A2*), and guanosine diphosphate-fucose (*SLC35C1*) were found to be upregulated.

Moreover, a large number of growth factors and receptors were overexpressed in UMC-11 compared with H835 cells, including members of the epidermal growth factor (EGF) family, insulin-like growth factor (IGF) family, neuropeptides, and others. In particular, EGF receptor (*EGFR*), v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (*ERBB3*), transforming growth factors ($TGF\alpha, \beta 1, \text{ and } \beta 2$), epiregulin (*EREG*), and amphiregulin (*AREG*) constitute a growth regulatory system, with heat shock protein 90 (*Hsp90*) and sprouty 2 (*SPRY2*) as modulators. A second independent growth factor pathway was provided by IGF2 and regulatory binding proteins (*IGFBP1, 3, 5, 6, and*

Table 1 Relative mRNA expression of selected genes in UMC-11 and H835 carcinoid cell lines

Gene symbol	Gene ID ABI 1700	Ratio of expression UMC-11/H835
Metabolism		
<i>LDHB</i>	167986	280
<i>LDH</i>	208956	55
<i>GAPDH</i>	236913	9
<i>HK1</i>	178010	8
<i>CS</i>	200851	6
<i>PDK4</i>	101060	12
Hypoxia		
<i>HIG1</i>	127432	12
<i>HIGD1A</i>	139216	14
<i>ARNT2</i>	205730	4
Proteases/protease inhibitors		
<i>PRSS1</i>	111365	2,636
<i>PRSS2</i>	109205	5,576
<i>PRSS3</i>	154524	1,861
<i>Serpin A2</i>	192373	11
<i>Serpin E2</i>	210342	13
<i>Serpin B6</i>	113902	5
<i>Serpin A10</i>	101912	18
<i>CTSL</i>	172735	32
<i>MMP13</i>	162909	20
<i>TIMP1</i>	134692	1,208
<i>TIMP3</i>	179538	57
Membrane transporters		
<i>ATP1B1</i>	199586	7
<i>ATP2A2</i>	142525	4
<i>ATP2B1</i>	102967	6
<i>ATP2C2</i>	146652	51
<i>FXYD2</i>	146341	84
<i>FXYD3</i>	126166	23
<i>ABCB1</i>	182279	44
<i>ABCC2</i>	115883	26
<i>ABCC3</i>	109767	41
<i>ABCD1</i>	165343	5
<i>ABCG1</i>	210662	4
<i>SLCO1A2</i>	192702	4
<i>SLCO2A1</i>	178284	33
<i>SLC1A6</i>	112712	916
<i>SLC18A1</i>	127370	27
<i>SLC4A2</i>	164313	4
<i>SLC4A11</i>	124838	16
<i>SLC12A7</i>	187225	6
<i>SLC20A2</i>	132288	5
<i>SLC35C1</i>	207403	8
Growth factors		
<i>EGFR</i>	136952	64
<i>ERBB3</i>	157084	22
<i>TGFA</i>	180395	17
<i>TGFB1</i>	170749	21
<i>TGFB3</i>	142790	8
<i>EREG</i>	100064	201
<i>AREG</i>	123143	147
<i>Hsp90</i>	148821	4
<i>SPRY2</i>	207231	33
<i>IGFII</i>	129922	814

(Continued)

Table 1 (continued)

Gene symbol	Gene ID ABI 1700	Ratio of expression UMC-11/H835
<i>IGFBP1</i>	202509	42
<i>IGFBP3</i>	104923	20
<i>IGFBP5</i>	170211	6
<i>IGFBP6</i>	150353	23
<i>IGF2BP2</i>	147646	24
<i>IL-8</i>	176899	115
<i>CALCB</i>	180834	6,969
<i>VIP</i>	144138	552
<i>NTS</i>	160562	93
<i>VGF</i>	174736	36
<i>NPW</i>	164302	6
<i>AGT</i>	196523	5
<i>SST</i>	157922	887
<i>FGF12</i>	138024	13
<i>ADCY2</i>	193946	618
<i>STIM2</i>	205035	4
S100 Ca²⁺-binding proteins		
<i>A2</i>	192373	11
<i>A4</i>	155850	170
<i>A6</i>	154326	87
<i>A10</i>	213843	185
<i>A11P</i>	187317	178
<i>P</i>	165541	254
<i>A14</i>	185644	36
<i>A16</i>	150790	432
Cytoskeleton		
<i>Keratin I</i>	231137	458
<i>Keratin II</i>	178654	103
<i>KRT7</i>	207298	38
<i>KRT8</i>	111916	14
<i>KRT18</i>	114812	171
<i>KRT19</i>	113888	80
<i>CDH1</i>	130505	300
<i>VILI</i>	191456	264
<i>CLDN4</i>	156519	21
<i>CLDN7</i>	163619	34
<i>CLDN20</i>	159987	74
<i>TUBB3</i>	203100	10
<i>TMSB4X</i>	141609	4
Sulfur metabolism		
<i>GSTT1</i>	163516	4
<i>GSTP1</i>	214807	225
<i>GRX</i>	188218	57
<i>ARSE1D</i>	139887	52
<i>SULF2</i>	116303	43
<i>GSTO2</i>	177000	41
<i>GLRX</i>	188218	57
<i>TST</i>	203712	8
Detoxification		
<i>AHR</i>	166278	39
<i>CYP26B1</i>	182081	28
<i>CYP2B6</i>	209472	19
<i>ALDH7 A1</i>	219563	30
<i>AKR7 A3</i>	179819	7
Topoisomerase I		
<i>TOP1</i>	179728	7
<i>TOPP1</i>	115448	5
<i>TOPP2</i>	236556	5

IGF2BP2), supplemented by a number of neuropeptides, namely vasointestinal peptide (*VIP*), neurotensin (*NTS*), *VGF* (*VGF* nerve growth factor inducible), and neuropeptide *W* (*NPW*). Interleukin-8 (*IL-8*), calcitonin-related polypeptide β (*CALCB*), angiotensin (*AGT*), and fibroblast growth factor 12 (*FGF12*) may in addition be involved in the regulation of cell proliferation, with *SST* as inhibitor. Increased overexpression of adenylate cyclase (*ADCY2*) pointed to an important role of this enzyme in signal transduction pathways of the growth stimulators.

S100 proteins regulate intracellular processes, such as cell growth and motility, cell cycle regulation, transcription, and differentiation. Twenty members have been identified so far, and altogether, S100 proteins represent the largest subgroup of the EF-hand Ca^{2+} -binding protein family. A unique feature of these proteins is that individual members are localized in specific cellular compartments from where some are able to relocate upon Ca^{2+} activation, thus transducing the Ca^{2+} signal temporally and spatially by interacting with different targets highly specific for each S100 protein. Some of the S100 Ca^{2+} -binding proteins overexpressed in the UMC-11 cells, namely *A2*, *A4*, *A6*, *A10*, *P*, *A14*, and *A16*, seem to have important functions in Ca^{2+} homeostasis, growth, and apoptosis. Differences in the expression of cytoskeleton constituents comprised type I keratins (*KRT18* and *KRT19*), type II keratins (*KRT7* and *KRT8*), cadherin 1 (*CDH1*), villin 1 (*VIL1*), claudins (*CLDN4*, 7, and 20), tubulin β 3 (*TUBB3*), thymosin β 4, X-linked chromosome (*TMSB4X*), and stromal interaction molecule 2 (*STIM2*).

Finally, detoxification of xenobiotics may be mediated by conjugation to sulphur-containing compounds, and the corresponding enzymes comprising glutathione *S*-transferase θ 1 (*GSTT1*), glutathione *S*-transferase π 1 (*GSTP1*), glutaredoxin (*GRX*), arylsulfatase (*ARSE/D/SULF2*), glutathione *S*-transferase Ω 2 (*GSTO2*), and thiosulfatase (*TST*) were found to be overexpressed in UMC-11 cells. Other mechanisms for the metabolism of drugs in UMC-11 cells included the cytochrome P450 (*CYP*) oxidoreductases (*CYP26B* and *CYP12B6*) that are regulated by the consistently overexpressed aryl hydrocarbon receptor (*AHR*), aldehyde dehydrogenase 7A1 (*ALDH7A1*), and aldo-keto reductase 7A3 (*AKR7A3*).

Topoisomerases are important targets of a range of cytotoxic drugs, in particular (*topoI*) for camptothecin derivatives like irinotecan and topotecan. Although *TOP 1* expression was elevated in UMC-11 cells, increased amounts of antisense transcripts stemming from *TOPP1* and *TOPP2* are expected to downregulate *TOP1* to induce drug resistance.

Discussion

Neuroendocrine lung tumors are highly refractory to chemotherapy, but the detailed mechanisms resulting in chemoresistance have not been fully characterized so far.¹¹ In contrast to the typical carcinoids, where multidrug resistance (*MDR*) is mediated by *P-gp* but not *MRP*, the atypical carcinoids exhibit cellular detoxification by *P-gp*, *MRP*, and *GST- π* expression.¹⁷ Both *Bcl-2* and *p53* proteins appear unchanged in carcinoids, suggesting that the apoptotic capacity conferred by these two gene products is not involved in chemoresistance. The chemoresistance of typical carcinoids was questioned, in general, based on their sensitivities observed in *in vitro* tests using these well-differentiated tumors.¹³ We recently compared the chemosensitivity profiles of the three carcinoid cell lines UMC-11, H727, and H835 and demonstrated marked chemoresistance to a wide range of cytotoxic drugs in UMC-11 cells in contrast to the other two chemosensitive cell lines.¹⁶ In this study, genome-wide gene expression analysis was used to search for candidate genes overexpressed in UMC-11 cells compared with H835 cells, and that would possibly hold the potential to confer chemoresistance.

Expression of hexokinase (*HK1*), an enzyme that traps glucose inside the cell by catalyzing phosphorylation to glucose 6-phosphate, and thus, maintains the downhill concentration gradient permitting facilitated glucose transport into cells for utilization, was higher in UMC-11 than in H835 cells.¹⁸ *GAPDH* catalyzes the conversion of glyceraldehyde 3-phosphate to D-glycerate 1,3-bisphosphate during the sixth step of glycolysis. *LDH/LDHB* catalyzes the conversion of L-lactate and nicotinamide adenine dinucleotide (*NAD*) to pyruvate and *NADH* in the final step of anaerobic glycolysis. This enzyme normally converts pyruvate, the final product of glycolysis, to lactate under hypoxic conditions. *PDK4* is a member of the *PDK/BCKDK* protein kinase family and encodes a mitochondrial protein with a histidine kinase domain.¹⁹ This protein inhibits the *PD* complex (*PDC*) by phosphorylating one subunit, which contributes to the regulation of glucose metabolism. The *PDC* converts pyruvate to acetyl coenzyme A (acetyl-CoA) by decarboxylation. Acetyl-CoA may then enter into the citric acid cycle for cellular respiration, thereby the glycolytic metabolic pathway is linked to the citric acid cycle and energy released in the form of *NADH* *PD*. In summary, high expression of these enzymes may indicate a shift of the cellular metabolism to increased uptake and catabolization of glucose.

Tumor cells exhibit aerobic glycolysis frequently (Warburg effect), and according to our results, the increased expression of a number of relevant genes corroborate

this metabolic shift. Unlike in H835 cells, *HIGD1A* is overexpressed in UMC-11 cells. *HIG1* was found as a novel gene, with unknown function induced by hypoxia and glucose deprivation in human cervical epithelial cells *in vitro*.²⁰ Hypoxia-induced transcription of the HIF-target genes *HIGD1A*, egl nine homolog 1 (*EGLN1*), Bcl2-interacting-protein 3 (*BNIP3*), and phosphofructokinase 1 is independent of the CH1 domain of CBP/p300, whereas stanniocalcin 1 and *SLC2A1* (glucose transporter 1) were moderately affected by the alteration of this transcriptional coactivator.²¹ Similarly, *EGLN1*, *HIG1*, and prolyl 4-hydroxylase are induced by treatment with nickel.²² In good agreement with *HIGD1A* expression, abundant transcripts of *ARNT2*, a member of the basic-helix-loop-helix-Per-Arnt-Sim (bHLH-PAS) superfamily of transcription factors that was observed in UMC-11 cells, heterodimerize with HIF-1 in the nucleus and, thus, promote expression of oxygen-responsive genes. In contrast to HK1, *GAPDH* is known to be induced by hypoxia or nickel.^{23,24} Therefore, UMC-11 cells clearly showed signs of aerobic glycolysis and induction of hypoxia-induced genes under aerobic conditions.²⁵

Most cancers exhibit elevated protease levels that contribute to certain aspects of tumor behavior in regard to growth, metastasis, and angiogenesis. Increased expression of the CTSs of the cysteine protease family, such as CTSL, correlates with invasion and migration of highly metastatic B16 melanoma cells.²⁶ Trypsin 1 and 2, serine protease 3 (*PRSS1*, 2, and 3), and *MMP13* were preferentially expressed in UMC-11 but not in H835 cells. Trypsin is implicated in colorectal carcinogenesis and promotes growth and dissemination of various cancers.²⁷ Furthermore, trypsin expression is an indicator of poor prognosis and shorter disease-free survival of colorectal cancer patients. Trypsin seems to act either directly by the digestion of type I collagen or indirectly by the activation of other proteinase cascades like MMPs. Stimulated by trypsin, both MMPs and protease-activated receptor 2 may activate the mitogen-activated protein kinase–extracellular signal-regulated protein kinase (MAPK-ERK) pathway through EGFR. MMPs may play an important role in both transformation from adenoma to carcinoma and initiation of invasion and metastasis. Upregulation of *MMP13* at the tumor-bone interface is crucial for tumor-induced osteolysis, which suggests that *MMP13* is a potential therapeutic target for breast cancer bone metastasis.²⁸ Tumor cell proteases are under tight regulation by proteinase inhibitors like TIMP2 and 3, both acting on *MMP13*.²⁹ Moreover, the highly expressed serpins (serine protease inhibitors) A1, A10, E2, and F1 are proteins with

similar structures that were first identified as inhibitors.³⁰ *SERPINA10* was one of the six novel marker genes for neuroendocrine carcinoma cells comprising paraneoplastic antigen *MA2* and testican 1 precursor (*SPOCK1*) among others.³¹ Overexpression of these proteases in conjunction with their regulatory inhibitors in UMC-11 cells pointed to a highly metastatic and aggressive phenotype.

The solute carrier, human organic anion transporting polypeptide *SLCO1A2* is highly expressed in the intestine, kidney, cholangiocytes, and the blood–brain barrier.³² This localization suggests that the transporter may be crucial for the distribution of clinically important drugs, besides shuttling bile acids. *SLCO2A1* transports PGs like PGE2 that was identified as the principal prostanoid promoting cell growth and survival in colorectal tumors by increasing Bcl-2 expression, which promotes cell survival under hypoxic conditions.³³ The other solute carriers overexpressed in UMC-11 cells are involved in the maintenance of ion homeostasis (Na⁺, K⁺, H⁺, and others), with no clear relation to chemoresistance.

MDR of tumor cells against a whole group of cytotoxic compounds is mediated by ABC efflux pumps.³⁴ P-gp (*ABCB1*), encoded by the *MDR1* gene, was the first such transporter detected. Determination of *MDR1* mRNA in human cancers revealed elevated expression in untreated, intrinsically drug-resistant tumors, including those derived from carcinoid tumors.³⁵ Further studies resulted in the characterization of the MRPs in some drug-selected cancer cell lines.³⁶ UMC-11 cells expressed *ABCC2* (MRP2) and *ABCC3* (MRP3) at higher levels than the drug-sensitive H835 cell line. MRPs appear to mediate glutathione (GSH) homeostasis and the efflux of oxidized GSH derivatives (eg, glutathione disulfide, *S*-nitrosoglutathione, and glutathione-metal complexes) and other glutathione *S*-conjugates.³⁷ Among the many processes, apoptosis, cell proliferation, and differentiation are influenced by GSH transporters. MRP gene expression was detected in almost all lung cancer cell lines, including carcinoids and normal lung tissue.³⁶ Furthermore, *ABCG1* and *ABCD1* are involved in the transport of lipids. In conclusion, MDR in UMC-11 cells seems to be partially effectuated by the classical ABC drug efflux pumps.

UMC-11 cells exhibited higher expression of *ATP1B1* encoding the Na⁺/K⁺-ATPase that exchanges three intracellular sodium for two extracellular potassium ions and is upregulated by cyclic adenosine monophosphate (cAMP). It serves as a signal transducer, regulates cell adhesion, and its aberrant expression and activity are implicated in the development and progression of different cancers.³⁸ Inhibition of this pump by cardiac glycosides reduces tumor metastasis, which

is possibly due to the sensitization to anoikis.³⁹ Altered ion gradients were also proposed as a potential cause of resistance to chemotherapy.⁴⁰ Furthermore, inhibition of Na⁺/K⁺-ATPase markedly reduces intracellular cisplatin accumulation.⁴¹ A hemisynthetic cardenolide shows high anticancer activity in cells expressing diverse forms of MDR, which is either conferred by inherent overexpression of selected drug transporter proteins or induced by a range of chemotherapeutic agents.⁴² Ion transport by Na⁺/K⁺-ATPase is modulated by a regulatory subunit belonging to the FXYD protein family.⁴³ UMC-11 cells showed high levels of *FXYD2* and *FXYD3* constituting the Na⁺/K⁺-ATPase γ -subunit and an ion pump regulator, highly expressed in breast cancers and responsible for cancer cell proliferation, respectively.⁴⁴ The other ion pumps overexpressed in UMC-11 cells namely *ATP2A2*, *B1*, and *C2* are responsible for the maintenance of cytoplasmic Ca²⁺ homeostasis.

Growth factors and their cognate receptors do not confer chemoresistance, but since they determine the proliferation rate, they constitute interesting targets for chemotherapy. The EGF/EGFR and ERBB3 growth factor system, as found overexpressed in UMC-11 cells, comprises a range of receptors and mitogenic factors including TGF α and others. The coexpressed factors TGF β 1 and β 2 are involved in the regulation of many physiological processes like cell growth, cell differentiation, and extracellular matrix production among others.⁴⁵ Moreover, TGF β may function as tumor suppressor or promotor depending on the type, differentiation state, and physiological characteristics of target cells.⁴⁶ The ErbB ligand epiregulin, found in UMC-11 cells, is highly expressed in non-small cell lung carcinoma (NSCLC) and correlates with nodal metastasis and a shorter duration of survival.⁴⁷ The related and coexpressed EGFR/TGFR ligand, amphiregulin, was found to predict NSCLC resistance to gefitinib and to suppress apoptosis by sequestration of BAX in the cytoplasm.⁴⁸ EGFR and activated EGFR (p-EGFR) were expressed in both well-differentiated gastrointestinal carcinoids and pancreatic endocrine tumors in primary and metastatic specimens with a poor prognosis.⁴⁹ The role of EGFR was studied in pulmonary typical and atypical carcinoid tumors.⁵⁰ Analysis showed that approximately half of typical carcinoids and one-third of atypical carcinoids produce EGFR, and all of the tumors exhibit moderate to intense staining for ErbB3 and ErbB4 but lack expression of ErbB2. High expression of the chaperone Hsp90 stabilizes oncogenic kinases and mutant EGFR driving proliferation of lung cancer cells.⁵¹ It was recently demonstrated that mutant EGFR is a Hsp90 target. In addition, SPRY1 seems to be operative in the regulation of EGFR signaling.⁵²

Another growth factor system frequently overexpressed in cancers is represented by the IGFs. IGF2 and a number of associated regulatory IGF-binding proteins (*IGFBP1*, 3, 5, 6, and *IGF2BP1/2*) were elevated in UMC-11 cells. Expression of *IGFBP2* along with low amounts of *IGFBP1* was found in all carcinoid samples in association with varying occurrences of *IGF1R*, *IGF2R*, and *IGFBP6*.^{53,54} *CALCB* was reported to play an important role in the proliferation of various types of epithelial and endothelial cells.⁵⁵ In an *in vitro* study, calcitonin-gene related peptide increased the proliferation of A549 alveolar epithelial cells in a dose-dependent and time-dependent manner.⁵⁶ IL-8 is a chemokine and angiogenic factor that also functions as an autocrine growth factor in several human cancers. In lung cancer, all NSCLC cell lines produced IL-8, in contrast to low levels of IL-8 in SCLC cell lines despite expression of the IL-8 receptors CXCR1 and CXCR2.⁵⁷ FGF12 is a FGF-homologous factor, which interacts with the intracellular kinase scaffold protein islet brain-2 and voltage-gated sodium channels.⁵⁸ UMC-11 cells produce AGT that may influence tumor growth and metastasis in a tissue-specific and tumor-specific manner.⁵⁹ In contrast, SST released by UMC-11 cells counteracts signaling of many other growth factors that contribute to proliferation, such as prolactin, IGF, TGF α and β , platelet-derived growth factor, EGF, and vascular endothelial growth factor (VEGF).

Because carcinoids resemble neuroendocrine tumors, the high expression of neuropeptides comprising VIP, NTS, VGF, and NPW by UMC-11 cells is expected to contribute significantly to autocrine growth stimulation. VIP causes increased proliferation of human breast and lung cancer cells *in vitro*.⁶⁰ It binds to cancer cells with high affinity and increases cAMP and gene expression of c-fos, c-jun, c-myc, and VEGF. SCLC, which is a neuroendocrine cancer, produces and secretes gastrin releasing peptide (GRP), NTS, and adrenomedullin (AM) as autocrine growth factors.⁶¹ Most of these neuropeptides are detectable in serum samples of carcinoid patients.⁶² GRP, NTS, and AM bind to G-protein-coupled receptors triggering increased phosphatidylinositol (PI) turnover or elevation of cAMP in SCLC cells. Addition of GRP, NTS, or AM to SCLC cells causes altered expression of nuclear oncogenes like c-fos and stimulation of growth.⁶³ Analysis of peptides secreted by the large-cell neuroendocrine carcinoma cell line revealed 2 fragments that were demonstrated to be parts of VGF, which is usually expressed in nerve cells or neuroendocrine cells.⁶⁴ Reverse transcription-polymerase chain reaction of lung cancer cell lines showed that VGF mRNA was expressed only in neuroendocrine carcinoma-derived cells. Neuropeptide

B (NPB) and NPW are the endogenous ligands of the 2 G-protein-coupled receptors GPR7 and GPR8 and activate protein kinase A and protein kinase C (PKC) signaling.⁶⁵ NPB and NPW were reported to stimulate tyrosine kinase and MAPK activities, mediating the proliferative and anti-apoptotic effects of NPB and NPW.

Cell type-specific differences exist among the various signal transduction pathways, comprising cAMP, hydrolysis of PI mobilization of intracellular calcium, and tyrosine phosphorylation, and, moreover, different receptors for the same trigger may be linked to different signal transduction pathways.^{66,67} Basically, the mitogenic signal of neuropeptides is transmitted into the cell via specific receptors that couple to heterotrimeric G proteins. Subsequent activation of phospholipase C- β influences the activation of PKC and the elevation of intracellular calcium. The antiproliferative effect of the Ca²⁺-channel blocker verapamil was investigated *in vitro* on 3 human lung cancer cell lines.⁶⁸ Verapamil inhibited cell proliferation in the neuroendocrine cancer cell line H727 in the nM range. STIM2 overexpressed in UMC-11 cells functions as highly sensitive Ca²⁺ sensor in the endoplasmic reticulum and regulates the ion concentration in conjunction with different pumps. Compared with H835, UMC-11 cells showed high expression of adenylate cyclase, establishing cAMP as an important second messenger of growth signals in these resistant carcinoid cells. In conclusion, UMC-11 cells seem to rely on EGF-related, IGF-related, and neuropeptide growth factors for stimulation of proliferation, and this multitude of autocrine and paracrine loops is expected to impede antiproliferative therapy by kinase inhibitors.

Overexpression of a large number of S100 Ca²⁺-binding proteins in UMC-11 cells pointed to their important functions in cell biology and possibly drug resistance of carcinoids. Intracellular Ca²⁺ seems to be permanently elevated in UMC-11 cells in response to continuous stimulation by growth factors. Downregulation of proapoptotic genes such as serine/threonine kinase 17a and *BNIP3* in association with *S100P* was reported to be linked to oxaliplatin resistance in the THC8307/L-OHP colon cancer cell line, and 8.7-fold overexpression of S100 protein family members was demonstrated in proteome analysis of cisplatin-resistant ovarian cancer cells.^{69,70} Furthermore, pancreatic ductal adenocarcinoma showed a correlation between decreased expression of *BNIP3* and chemoresistance through repression by *S100A2* and *S100A4*.⁷¹ In support of these findings, *S100A4* expression was a predictor of poor prognosis for T1N0M0 breast cancer patients.^{72,73} In conclusion, the expression of a number of S100 proteins may contribute to the

broad chemoresistance of carcinoid cells by downregulation of proapoptotic factors.

Numerous members of the cytoskeleton are preferentially expressed in UMC-11 vs H835 cells, including type I and II cytokeratins, CLDNs, VIL, CDH1, TUBB3, and thymosin β 4. Most of these components may reflect differences in the histological subtypes of UMC-11 and H835 cells; however, especially TUBB3 overexpression represents a marker of resistance to microtubule-targeting drugs *in vitro*, *in vivo*, and clinically for many tumors, including breast cancer, and thymosin β 4 proves to be a gene associated with response to therapy in ovarian cancer.^{74,75}

Sulfur-containing molecules such as cysteine, methionine, GSH, metallothioneins, and albumin bind platinum-based compounds and reduce therapeutic efficacy at the level of uptake, excretion, resistance, and toxicity.⁷⁶ Studies showed that variability in survival can in part be explained by polymorphisms in genes encoding proteins involved in degradation of drugs. Most importantly, such polymorphisms of drug-metabolizing enzymes and transporters demonstrated to influence survival after cancer treatment compass genes of the phase II detoxification enzymes, GSTs.⁷⁷ For example, the *GSTM1*-deficient and *GSTT1*-deficient genotypes have a clear association with longer overall survival in patients treated with respective substrates, such as alkylating agents and platinum compounds. Likewise, genetic polymorphisms of *GSTP1* and *GSTA1* are also linked with increased overall survival in patients with different malignancies. Levels of thioredoxin (TRX) and GRX were elevated in pancreatic ductal carcinoma tissues compared with pancreatic cystadenocarcinoma or normal pancreatic tissue. Furthermore, cisplatin-resistant subclones of HeLa cells had higher expression of TRX and GRX compared with the parental cells.⁷⁸

AHR encodes a ligand-activated transcription factor binding to the xenobiotic response element-containing promoter region that is involved in the regulation of biological responses to planar aromatic hydrocarbons. This receptor has been shown to regulate levels of xenobiotic-metabolizing enzymes like CYP, of which CYP2B1 and 2B6 were comparatively overexpressed in UMC-11 cells.⁷⁹ Human ALDH7A1 protects against hyperosmotic stress through generation of osmolytes and metabolism of toxic aldehydes.⁸⁰ Human ALDH7A1 expression in Chinese hamster ovary cells attenuated osmotic stress-induced apoptosis caused by increased extracellular concentrations of sucrose or sodium chloride. AKRs are phase I drug-metabolizing enzymes for a variety of carbonyl-containing drugs and are implicated in cancer chemotherapeutic drug resistance. They are

stress-regulated genes and play a pivotal role in the cellular response to osmotic, electrophilic, and oxidative stress. The 10 known human AKR enzymes can turnover a range of substrates, including drugs, carcinogens, and reactive aldehydes. AKRs like AKR7A3 are soluble NAD(P)H oxidoreductases that primarily reduce aldehydes and ketones to primary and secondary alcohols, respectively.⁸¹

Eukaryotic topo I, a DNA unwinding enzyme, is essential for several cellular functions and is the target of camptothecin derivatives like irinotecan and topotecan. However, regulation of topo I activity was not known for a long time. In an effort to identify potential regulators of *TOP1* activity, at least 2 antisense transcripts coded by *TOP1* pseudogenes were described.⁸² Although the function of these *TOP1* antisense transcripts has remained unknown, recent studies of naturally occurring antisense RNA demonstrated a number of potential regulatory roles. Downregulation of topo I in carcinoids would increase resistance to camptothecin derivatives.

Conclusion

Multidrug-resistant UMC-11 cells seem to use classical drug transporters, such as P-gp and MRP, drug conjugation and metabolism systems, and possibly new mechanisms, such as suppression of apoptosis by S100 proteins and downregulation of topo I, by its own pseudogene transcripts to achieve chemoresistance. The genome-wide search for drug resistance-associated genes described here provides new evidence for possible targets to circumvent the chemoresistant phenotype of carcinoids. Functional involvement of the candidate genes found needs to be verified by experiments deleting the corresponding transcripts, and, furthermore, it remains to be investigated how far these results apply to other neuroendocrine tumors.⁸³

Acknowledgment and disclosure

This study was supported by a fund of the Jubilaeumsfonds (OENB, grant # 13345). The authors report no conflicts of interest associated with this work.

References

- Öberg K. Diagnosis and treatment of carcinoid tumors. *Expert Rev Anticancer Ther.* 2003;3:863–877.
- Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. *Gastroenterology.* 2005;128:1717–1751.
- Pinchot SN, Holen K, Sippel RS, et al. Carcinoid tumors. *Oncologist.* 2008;13:1255–1269.
- Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. *Oncologist.* 2005;10:123–131.
- Granberg D, Öberg K. Neuroendocrine tumours. *Cancer Chemother Biol Response Modif.* 2005;22:471–483.
- Capella C, Heitz PU, Hofler H, et al. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. *Virchows Arch.* 1995; 425:547–560.
- Warren WH, Gould VE, Faber LP, et al. Neuroendocrine neoplasms of the bronchopulmonary tract: a classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. *J Thorac Cardiovasc Surg.* 1985;89:819–825.
- Smolle-Juttner FM, Popper H, Klemen H, et al. Clinical features and therapy of “typical” and “atypical” bronchial carcinoid tumors (grade 1 and grade 2 neuroendocrine carcinoma). *Eur J Cardiothorac Surg.* 1993;7:121–125.
- Detterbeck FC. Management of carcinoid tumors. *Ann Thorac Surg.* 2010;89:998–1005.
- Moertel CG, Sauer WG, Dockerty MB, et al. Life history of the carcinoid tumor of the small intestine. *Cancer.* 1961;14:901–912.
- Bertino EM, Confer PD, Colonna JE, et al. Pulmonary neuroendocrine/ carcinoid tumors: a review article. *Cancer.* 2009;115:4434–4441.
- Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. *J Clin Oncol.* 1983;1:727–740.
- Lyons JM III, Abergel J, Thomson JL, et al. In vitro chemoresistance testing in well-differentiated carcinoid tumors. *Ann Surg Oncol.* 2009; 16:649–655.
- Kosmidis PA. Treatment of carcinoid of the lung. *Curr Opin Oncol.* 2004;16:146–149.
- Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. *J Clin Oncol.* 2005;23: 4897–4904.
- Fiebiger W, Olszewski U, Ulsperger E, et al. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. *Clin Transl Oncol.* In press.
- Guigay J, Ruffie P, Regnard JF, et al. Chemoresistance mechanisms and neuroendocrine lung tumors (NELT). Paper presented at: 1995 ASCO Annual Meeting; 1995. Abstract 398.
- Furuta E, Okuda H, Kobayashi A, et al. Metabolic genes in cancer: their roles in tumor progression and clinical implications. *Biochim Biophys Acta.* 2010;1805:141–152.
- Roche TE, Hiromasa Y. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. *Cell Mol Life Sci.* 2007;64:830–849.
- Denko N, Schindler C, Koong A, et al. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. *Clin Cancer Res.* 2000;6:480–487.
- Kasper LH, Brindle PK. Mammalian gene expression program resiliency: the roles of multiple coactivator mechanisms in hypoxia-responsive transcription. *Cell Cycle.* 2006;5:142–146.
- Salnikow K, Davidson T, Zhang Q, et al. The involvement of hypoxia-inducible transcription factor-1-dependent pathway in nickel carcinogenesis. *Cancer Res.* 2003;63:3524–3530.
- Riddle SR, Ahmad A, Ahmad S, et al. Hypoxia induces hexokinase II gene expression in human lung cell line A549. *Am J Physiol Lung Cell Mol Physiol.* 2000;278:L407–L416.
- Graven KK, McDonald RJ, Farber HW. Hypoxic regulation of endothelial glyceraldehyde-3-phosphate dehydrogenase. *Am J Physiol.* 1998;274:C347–C355.
- Koh MY, Spivak-Kroizman TR, Powis G. HIF-1 α and cancer therapy. *Recent Results Cancer Res.* 2010;180:15–34.
- Yang Z, Cox JL. Cathepsin L increases invasion and migration of B16 melanoma. *Cancer Cell Int.* 2007;7:8.
- Soreide K, Janssen EA, Körner H, et al. Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. *J Pathol.* 2006;209:147–156.
- Nannuru KC, Futakuchi M, Varney ML, et al. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor- β signaling at the tumor-bone interface. *Cancer Res.* 2010;70:3494–3504.

29. Voland P, Besig S, Rad R, et al. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival. *Neuroendocrinology*. 2009;89:66–78.
30. Oikonomopoulou K, Diamandis EP, Hollenberg MD. Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. *Biol Chem*. 2010;391:299–310.
31. Leja J, Essaghir A, Essand M, et al. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. *Mod Pathol*. 2009;22:261–272.
32. Franke RM, Scherkenbach LA, Sparreboom A. Pharmacogenetics of the organic anion transporting polypeptide 1A2. *Pharmacogenomics*. 2009;10:339–344.
33. Shimizu S, Eguchi Y, Kosaka H, et al. Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. *Nature*. 1995;374:811–813.
34. Jones PM, O'Mara ML, George AM. ABC transporters: a riddle wrapped in a mystery inside an enigma. *Trends Biochem Sci*. 2009;34:520–531.
35. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. *J Natl Cancer Inst*. 1989;81:116–124.
36. Giaccone G, van Ark-Otte J, Rubio GJ, et al. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. *Int J Cancer*. 1996;66:760–767.
37. Ballatori N, Krance SM, Marchan R, et al. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. *Mol Aspects Med*. 2009;30:13–28.
38. Mijatovic T, Ingrassia L, Facchini V, et al. Na⁺/K⁺-ATPase α subunits as new targets in anticancer therapy. *Expert Opin Ther Targets*. 2008;12:1403–1417.
39. Simpson CD, Mawji IA, Anyiwe K, et al. Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. *Cancer Res*. 2009;69:2739–2747.
40. Brouillard F, Tondelier D, Edelman A, et al. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells. *Cancer Res*. 2001;61:1693–1698.
41. Ahmed Z, Deyama Y, Yoshimura Y, et al. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na⁽⁺⁾/K⁽⁺⁾-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B. *Cancer Chemother Pharmacol*. 2009;63:643–650.
42. Mijatovic T, Jungwirth U, Heffeter P, et al. The Na⁺/K⁺-ATPase is the Achilles heel of multi-drug-resistant cancer cells. *Cancer Lett*. 2009;282:30–34.
43. Geering K. FXYD proteins: new regulators of Na-K-ATPase. *Am J Physiol Renal Physiol*. 2006;290:F241–F250.
44. Yamamoto H, Okumura K, Toshima S, et al. FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues. *Biol Pharm Bull*. 2009;32:1148–1154.
45. Blobel GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. *N Engl J Med*. 2000;342:1350–1358.
46. Elliott RL, Blobel GC. Role of transforming growth factor β in human cancer. *J Clin Oncol*. 2005;23:2078–2093.
47. Zhang J, Iwanaga K, Choi KC, et al. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. *Cancer Prev Res (Phila Pa)*. 2008;1:201–207.
48. Busser B, Sancey L, Josserand V, et al. Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers. *Mol Ther*. 2010;18:528–535.
49. Papouchado B, Erickson LA, Rohlinger AL, et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. *Mod Pathol*. 2005;8:1329–1335.
50. Rickman OB, Vohra PK, Sanyal B, et al. Analysis of ErbB receptors in pulmonary carcinoid tumors. *Clin Cancer Res*. 2009;15:3315–3324.
51. Shimamura T, Shapiro GI. Heat shock protein 90 inhibition in lung cancer. *J Thorac Oncol*. 2008;3:S152–S159.
52. Egan JE, Hall AB, Yatsula BA, Bar-Sagi D. The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. *Proc Natl Acad Sci U S A*. 2002;99:6041–6046.
53. Wulbrand U, Remmert G, Zöfel P, et al. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. *Eur J Clin Invest*. 2000;30:729–739.
54. Camidge DR, Dziadziuszko R, Hirsch FR. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. *Clin Lung Cancer*. 2009;10:262–272.
55. Kawanami Y, Morimoto Y, Kim H, et al. Calcitonin gene-related peptide stimulates proliferation of alveolar epithelial cells. *Respir Res*. 2009;10:8.
56. Aiyar N, Disa J, Stadel JM, et al. Calcitonin gene-related peptide receptor independently stimulates 3',5'-cyclic adenosine monophosphate and Ca²⁺ signaling pathways. *Mol Cell Biochem*. 1999;197:179–185.
57. Zhu YM, Webster SJ, Flower D, et al. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. *Br J Cancer*. 2004;91:1970–1976.
58. Olsen SK, Garbi M, Zampieri N, et al. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. *J Biol Chem*. 2003;278:34226–34236.
59. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. *Carcinogenesis*. 2008;29:1675–1684.
60. Moody TW, Hill JM, Jensen RT. VIP as a trophic factor in the CNS and cancer cells. *Peptides*. 2003;24:163–177.
61. Myers RM, Shearman JW, Kitching MO, et al. Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. *ACS Chem Biol*. 2009;4:503–525.
62. Calhoun K, Toth-Fejel S, Cheek J, et al. Serum peptide profiles in patients with carcinoid tumors. *Am J Surg*. 2003;186:28–31.
63. Moody TW. Peptide hormones and lung cancer. *Panminerva Med*. 2006;48:19–26.
64. Matsumoto T, Kawashima Y, Nagashio R, et al. A new possible lung cancer marker: VGF detection from the conditioned medium of pulmonary large cell neuroendocrine carcinoma-derived cells using secretome analysis. *Int J Biol Markers*. 2009;24:282–285.
65. Andreis PG, Rucinski M, Neri G, et al. Neuropeptides B and W enhance the growth of human adrenocortical carcinoma-derived NCI-H295 cells by exerting MAPK p42/p44-mediated proliferogenic and antiapoptotic effects. *Int J Mol Med*. 2005;16:1021–1028.
66. Gudermann T, Roelle S. Calcium-dependent growth regulation of small cell lung cancer cells by neuropeptides. *Endocr Relat Cancer*. 2006;13:1069–1084.
67. Townsend CM Jr, Bold RJ, Ishizuka J. Gastrointestinal hormones and cell proliferation. *Surg Today*. 1994;24:772–777.
68. Schüller HM, Orloff M, Reznik GK. Antiproliferative effects of the Ca²⁺/calmodulin antagonist B859-35 and the Ca⁽²⁺⁾-channel blocker verapamil on human lung cancer cell lines. *Carcinogenesis*. 1991;12:2301–2303.
69. Tang H, Liu YJ, Liu M, et al. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP. *Anticancer Drugs*. 2007;18:633–639.
70. Stewart JJ, White JT, Yan X, et al. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. *Mol Cell Proteomics*. 2006;5:433–443.
71. Mahon PC, Baril P, Bhakta V, et al. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. *Cancer Res*. 2007;67:6786–6795.
72. Guo B, Villeneuve DJ, Hembruff SL, et al. Cross-resistance studies of isogenic drug-resistant tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. *Breast Cancer Res Treat*. 2004;85:31–51.
73. Lee WY, Su WC, Lin PW, et al. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. *Oncology*. 2004;66:429–438.

74. Stengel C, Newman SP, Leese MP, et al. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. *Br J Cancer*. 2010;102:316–324.
75. Györfy B, Dietel M, Fekete T, et al. A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. *Int J Gynecol Cancer*. 2008;18:1215–1233.
76. Wang X, Guo Z. The role of sulfur in platinum anticancer chemotherapy. *Anticancer Agents Med Chem*. 2007;7:19–34.
77. Ekhardt C, Rodenhuis S, Smits PH, et al. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. *Cancer Treat Rev*. 2009;35:18–31.
78. Nakamura H, Bai J, Nishinaka Y, Ueda S, et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. *Cancer Detect Prev*. 2000;24:53–60.
79. Njar VC. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. *Mini Rev Med Chem*. 2002;2:261–269.
80. Bocker C, Lassen N, Estey T, et al. Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress. *J Biol Chem*. 2010;285:18452–18463.
81. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. *Annu Rev Pharmacol Toxicol*. 2007;47:263–292.
82. Zhou BS, Beidler DR, Cheng YC. Identification of antisense RNA transcripts from a human DNA topoisomerase I pseudogene. *Cancer Res*. 1992;52:4280–4285.
83. Shanker M, Willcutts D, Roth JA, et al. Drug resistance in lung cancer. *Lung Cancer: Targets and Ther*. 2010;1:23–36.

Lung Cancer: Targets and Therapy

Dovepress

Publish your work in this journal

Lung Cancer: Targets and Therapy is an international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. Specific topics covered in the journal include:

Submit your manuscript here: <http://www.dovepress.com/lung-cancer-targets-and-therapy-journal>

Epidemiology, detection and screening; Cellular research and biomarkers; Identification of biotargets and agents with novel mechanisms of action; Optimal clinical use of existing anticancer agents, including combination therapies; Radiation and surgery; Palliative care; Patient adherence, quality of life, satisfaction; Health economic evaluations.